Alstonine Derivatives and Salts Thereof
AssigneeNapo Pharmaceuticals, Inc.
InventorsSteven King, Karen Brunke, Elaine Elisabetsky, Maurice M. Iwu
Life of this patent
Estimating the term…
Abstract
The present disclosure is concerned with alstonine, alstonine analogs, and salts thereof for the treatment of various disorders where changes in 5-HT2A/5-HT2C receptor signaling and/or dopamine transporter activity may be beneficial such as, for example, psychotic disorders, epilepsy, and anxiety disorders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Claims29
A compound having a structure represented by a formula:
- wherein X is selected from halogen, acetate, alginate, ascorbate, benzoate, carbonate, cinnamate, citrate, diphosphate, fumarate, gluconate, lactate, laurate, malate, maleate, mesylate, myristate, nitrate, palmitate, phosphate, propionate, sorbate, succinate, sulfate, tartrate, and a conjugate base of a phenolic acid;
- and
- wherein R is C1-C16 alkyl,
- provided that when R is methyl then X is not Cl.
(canceled)
(canceled)
(canceled)
(canceled)
18-19. (canceled)
The compound of claim Error! Reference source not found, wherein X is selected from cinnamate, succinate, and trimethoxybenzoate.
(canceled)
25-58. (canceled)
60-65. (canceled)
The method of claim 0, wherein administering is via transdermal or intradermal administration.
The method of claim 0, wherein administering is via a transdermal patch or a microneedle array.
68-120. (canceled)
Dependencies are inferred from the claim text.